Cambridge Confidence in Concept: translating innovative science into patient benefit

Lead Research Organisation: University of Cambridge

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50
 
Description "Small molecule allosteric modulators of incretin receptors as treatments for type II diabetes"
Amount $1,000,000 (USD)
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 09/2019 
 
Description A novel therapeutic platform to increase tumour immunogenicity
Amount £14,800 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2020 
End 03/2021
 
Description Bioassay of cervid prions in Drosophila
Amount £476,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start  
 
Description COMMIT - Continuous Online Metabolite Monitoring.
Amount £1,137,648 (GBP)
Funding ID NIHR200986 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2020 
End 03/2023
 
Description CRUK Early Detection Primer Award
Amount £100,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Cambridge Cardiovascular Pump Priming Grant
Amount £25,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2020 
End 07/2020
 
Description Development of an artificial intelligence solution for the analysis of histopathological images in coeliac disease
Amount £35,834 (GBP)
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start  
 
Description EPSRC Impact Acceleration Account Follow-on Fund University of Cambridge
Amount £50,000 (GBP)
Organisation ESRC Impact Acceleration Account Cambridge 
Sector Academic/University
Country United Kingdom
Start 08/2019 
 
Description EPSRC Project grant
Amount £783,024 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 08/2020 
 
Description Funding for a regulatory strategy report commissioned from Global Regulatory Services (GRS) Ltd
Amount £15,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2021 
 
Description Identification of a T/ B-cell signal of Coronavirus immunity for better prediction of an individual's Coronavirus immune status
Amount £65,000 (GBP)
Organisation Trustee for Snudden Family Trust 
Sector Charity/Non Profit
Country Australia
Start  
 
Description Image analysis in coeliac disease, with the ultimate aim of combining this with the TCR analysis funded by the MRC CiC for optimum diagnosis.
Amount £250,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start  
 
Description Molecular mechanisms controlling peptide selection for immune recognition
Amount £1,947,412 (GBP)
Funding ID 219479/Z/19/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2020 
End 04/2025
 
Description NIH Programme Grant - Detection of blood-borne prions
Amount £1,000,200 (GBP)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start  
 
Description Neonatal Wireless Transmission System
Amount £10,000 (GBP)
Organisation United Kingdom Research and Innovation 
Department Global Challenges Research Fund
Sector Public
Country United Kingdom
Start 06/2019 
 
Description Purchase of an Agilent TapeStation
Amount £10,000 (GBP)
Organisation Pathological Society of Great Britain & Ireland 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Collaboration with ARUK drug discovery Institute 
Organisation Alzheimer's Research UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution This year we have new data demonstrating that trazodone can influence the protein eIF2B. eIF2B is made up of 2 copies of 5 separate subunits, and the combination and regulation of these 10 subunits has emerged as a novel site of regulation of protein synthesis. Our data shows that trazodone can influence the composition of the subunits of eIF2B, adding further evidence that this is where trazodone acts. However, we still haven't been able to show direct binding.
Collaborator Contribution We are collaborating with the ARUK drug discovery institute to try to resolve this, as they have been able to produce eIF2B protein efficiently, which should provide enough material for definitive experiments. The role of PDE6? is also being further explored.
Impact We have begun the PET scanning of control patients and patients with Alzheimer's disease. Unfortunately the COVID pandemic has put a temporary halt to the experiment but the scans we performed before the pandemic went extremely well and has so far supported our hypothesis. We hope to start testing trazodone in these patients a soon as possible, but it will likely require securing additional funding.
Start Year 2021
 
Description Research collaboration being developed with Brainlab AG 
Organisation Brainlab
Country Germany 
Sector Private 
PI Contribution We are currently working on using the AGORA code for the follow-on study for PRAM-GBM, which will complete in October 2020. 2021 update. The AGORA-RT work has been picked up as part of the CRUK funded RadNet radiotherapy research project, and is being incorporated into a multi-centre clinical trial called Hamlet.rt. This would open in 10 centres across the UK, and we await to hear news from CRUK regarding funding of the multi-centre expansion of the study,
Collaborator Contribution Research collaboration being developed with Brainlab AG. Brainlab have a new head of UK research collboarations and we have reached out to them in regards to the next planned PRAM-GBM study.
Impact We were unsuccessful in our application to MRC DPFS, and our aim is to obtain clinical data in the successor to the CRUK funded PRAM-GBM study. As above- the Agora-RT concepts are now part of the Hamlet.rt study, which is an NIHR CRN portfolio study of predictive radiomics in radiation therapy. No additional funding beyond that mentioned above. Awaiting on news of an additional £41,000 of funding from CRUK for multi-centre expansion of the study
Start Year 2020
 
Description SAS collaboration, likely to present at future SAS meetings. NPL collaboration 
Organisation SAS Trace Element Centre
Country United Kingdom 
Sector Private 
PI Contribution This project required the building of a new relationship between the clinical team and our industry collaborator (SAS), where have made significant steps forwards in establishing the computing infrastructure,
Collaborator Contribution Our weekly collaboration with SAS continues and we are close to reaching our defined goals. Future work will take these processes forward and look to develop key capabilities required for industrialisation. The most important of these is a transition from a predominantly manual, unidirectional prepossessing workflow; where data are labelled, processed and trained in steps, to one where data are ingested and processing steps are automatic within a shared platform that both the machine predictions and the human annotation can interact. Clearly, in our vision of a human-AI interface with an overseer correcting outputs, such a platform is essential for the final product, but, there are also huge gains in efficiencies offered by using a trained model to complete much annotation load, which can be corrected by a human and fed back to the model as new training examples
Impact Data library and the skills collaboration team between the clinical team and SAS. In our time so far we have been able to: 1. Establish local administrative and ethical approval for our work. 2. Install and develop the computing architecture required for this work. 3. Make progress towards a collaborative agreement between Cambridge University and SAS 4. Establish the collaboration team, with weekly meetings during which there is sharing of data, progress reporting and defined goal setting week by week. 5. Perform data extraction of the entire cohort the clinical images. 6. Initiate a collaboration between the university and NPL for the purposes of ensuring best practice for data management and setting novel standards for DICOM-pathology images. 7. Establish initial proof of principle capabilities in one of our 4 domains of image analysis
Start Year 2019
 
Description Takeda Pharmaceuticals commissioned an external company (Sandexis medicinal chemistry) to perform a lead likeliness, patent analysis and in silico ADME studies 
Organisation Takeda Pharmaceutical Company
Department Takeda Pharmaceutical Company Ltd
Country United Kingdom 
Sector Private 
PI Contribution We have made considerable progress on the functional aspects of the compounds. We have use pharmacological tools to determine the molecular basis of their action and screen for new compounds. However, to date our compounds, remain low potency. We have performed additional screens to try to enhance potency. We are now looking to screen these new compounds through the work of a newly recruited PhD student in our lab. Furthermore, a subset of the new molecules have shown negative allosteric activity which is also of commercial interest for obesity. We are looking to move these compounds forward in the 2 years. Data has progressed at a slower rate in 2020 due to Covid-19 restrictions. However, we have good evidence of potential for the negative allosteric activity and will be looking to assess their activity in adipose tissue.
Collaborator Contribution We have held discussion with Takeda Pharmaceuticals regarding validation of the GIPR PAMs. Takeda Pharmaceuticals commissioned an external company (Sandexis medicinal chemistry) to perform a lead likeliness, patent analysis and in silico ADME studies. • Takeda: 'Determine the role that RAMPs and ß-arrestins may perform in modulating GIPR-mediated signaling and or internalization in physiologically important tissues.' For a sum of ~ (>$850,000). But it is not finalised. Now signed G103360
Impact AZ and Takeda Pharmaceuticals Takeda Pharmaceuticals commissioned an external company (Sandexis medicinal chemistry) to perform a lead likeliness, patent analysis and in silico ADME studies. Following this report, compounds were exchanged with Takeda Pharmaceuticals and are currently undergoing validation in the Takeda assays. Furthermore, we have held discussion with AstraZeneca regarding these compounds and others in our portfolio. These discussions were at a very early phase+ AstraZeneca Science Catalyst but unfortunately will not be followed on
Start Year 2019
 
Description small molecule TLR4 antagonists for use in Alzheimer's disease and asthma 
Organisation Apollo Therapeutics
Country United Kingdom 
Sector Private 
PI Contribution We identified 2 leads plus 2 near neighbour compounds. We identified the novel binding site that these compounds bound to on the signalling domain of TLR4. This confirmed our hypothesis that the compounds bind directly to TLR4 and so de-risked investment in our project. Recombinant protein yields were sufficient for biophysical analysis and crystal trials which are underway for the follow up project with Apollo Therapeutics.
Collaborator Contribution Apollo invested ~£4M into this project to develop small molecule TLR4 antagonists for use in Alzheimer's disease and asthma. This project is ongoing
Impact During the course of the project in our other research work with David Klenerman we found that TLR4 antagonists may be a useful therapeutic in Alzheimer's and Parkinson's diseases. This, combined with our respiratory work, led to Apollo Therapeutics investing ~£4M to expand the drug discovery project. This work commenced in April 2018. The project with Apollo is ongoing. We have developed a number of potent TLR4 small molecule antagonists and are currently modifying them to achieve pharmacokinetic stability. The pharmacokinetic stability continues to be challenging and has resulted in us using different strategies to develop further TLR4 small molecule antagonist structures. Apollo have also generated a panel of inhibitory monoclonal antibodies against TLR4 to develop for clinical use. The small molecule drug discovery program and the antibody program are both very active at the moment. We continue to engage with Johnson and Johnson and Astra Zeneca who remain very interested in our project. In 2021 we hope to either have the project licensed to one of these two companies or to establish a spin out company to develop the TLR4 antagonists and/or antibodies further ourselves.
Start Year 2018
 
Description small molecule TLR4 antagonists for use in Alzheimer's disease and asthma 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution We identified 2 leads plus 2 near neighbour compounds. We identified the novel binding site that these compounds bound to on the signalling domain of TLR4. This confirmed our hypothesis that the compounds bind directly to TLR4 and so de-risked investment in our project. Recombinant protein yields were sufficient for biophysical analysis and crystal trials which are underway for the follow up project with Apollo Therapeutics.
Collaborator Contribution Apollo invested ~£4M into this project to develop small molecule TLR4 antagonists for use in Alzheimer's disease and asthma. This project is ongoing
Impact During the course of the project in our other research work with David Klenerman we found that TLR4 antagonists may be a useful therapeutic in Alzheimer's and Parkinson's diseases. This, combined with our respiratory work, led to Apollo Therapeutics investing ~£4M to expand the drug discovery project. This work commenced in April 2018. The project with Apollo is ongoing. We have developed a number of potent TLR4 small molecule antagonists and are currently modifying them to achieve pharmacokinetic stability. The pharmacokinetic stability continues to be challenging and has resulted in us using different strategies to develop further TLR4 small molecule antagonist structures. Apollo have also generated a panel of inhibitory monoclonal antibodies against TLR4 to develop for clinical use. The small molecule drug discovery program and the antibody program are both very active at the moment. We continue to engage with Johnson and Johnson and Astra Zeneca who remain very interested in our project. In 2021 we hope to either have the project licensed to one of these two companies or to establish a spin out company to develop the TLR4 antagonists and/or antibodies further ourselves.
Start Year 2018
 
Description small molecule TLR4 antagonists for use in Alzheimer's disease and asthma 
Organisation Johnson & Johnson
Department Neuroscience Johnson and Johnson
Country United States 
Sector Private 
PI Contribution We identified 2 leads plus 2 near neighbour compounds. We identified the novel binding site that these compounds bound to on the signalling domain of TLR4. This confirmed our hypothesis that the compounds bind directly to TLR4 and so de-risked investment in our project. Recombinant protein yields were sufficient for biophysical analysis and crystal trials which are underway for the follow up project with Apollo Therapeutics.
Collaborator Contribution Apollo invested ~£4M into this project to develop small molecule TLR4 antagonists for use in Alzheimer's disease and asthma. This project is ongoing
Impact During the course of the project in our other research work with David Klenerman we found that TLR4 antagonists may be a useful therapeutic in Alzheimer's and Parkinson's diseases. This, combined with our respiratory work, led to Apollo Therapeutics investing ~£4M to expand the drug discovery project. This work commenced in April 2018. The project with Apollo is ongoing. We have developed a number of potent TLR4 small molecule antagonists and are currently modifying them to achieve pharmacokinetic stability. The pharmacokinetic stability continues to be challenging and has resulted in us using different strategies to develop further TLR4 small molecule antagonist structures. Apollo have also generated a panel of inhibitory monoclonal antibodies against TLR4 to develop for clinical use. The small molecule drug discovery program and the antibody program are both very active at the moment. We continue to engage with Johnson and Johnson and Astra Zeneca who remain very interested in our project. In 2021 we hope to either have the project licensed to one of these two companies or to establish a spin out company to develop the TLR4 antagonists and/or antibodies further ourselves.
Start Year 2018
 
Description - CRUK Innovation Summit 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Ania Piskorz presented at the summit highlighting her entrepreneurship activities involving our recently created startup Tailor Bio and our support from the MRC through the CiC award. This activity created awareness of Ania's science in a commercial setting and has expanded our network and opportunities to commercialise the output of this study.
Year(s) Of Engagement Activity 2019
URL https://www.cancerresearchuk.org/funding-for-researchers/research-events-and-conferences/innovation-...
 
Description A novel split mode TFBAR device for quantitative measurements of prostate specific antigen in a small sample of whole blood 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Appearance on
- BBC Look East
- BBC Breakfast
Year(s) Of Engagement Activity 2020
 
Description Abstract selected for short-talk at Single Cell Biology Conference (Wellcome Sanger Institute) virtual edition. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Abstract selected for short talk Virtual edition presented by Carys Johnson, PhD Student at the Wellcome Sanger Institute.
Year(s) Of Engagement Activity 2020
 
Description Artemis-A - School visits (e.g Landmark International School, Fulbourn; School visit (Soham Village College, Soham) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact We have presented the Artemis-A and talked about the project in four secondary schools in the area (Cambridge, Ely).
These engagement activities were integral to the development of the app but also for informing plans to for how it would successfully be applied within secondary schools for the next stage of the project
Year(s) Of Engagement Activity 2019
 
Description Artemis-R 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact this is a network of researchers and practitioners who were interested in supporting mental health in schools.
These engagement activities were integral to the development of the app but also for informing plans to for how it would successfully be applied within secondary schools for the next stage of the project.
Year(s) Of Engagement Activity 2020
 
Description BPS-MPGPCR 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact This was a research focussed meeting attended by GPCR researchers and industry. This meeting was to disseminate scientific finds. It resulted in us initiated a strong collaboration with the Monash group lead by Sexton and Wootten.
Year(s) Of Engagement Activity 2018
 
Description British Neurosurgical Research Group Meeting 2019, John McIntyre Conference Centre, Edinburgh 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Poster - National neurosurgical/scientific conference. This MRC CiC project award ended on 30th April 2020. Conferences/meetings attended (at which we have presented our 31P MRS) before this date are listed above. No further conferences etc have been attended specifically on this 31P MRS project, due to Covid restrictions. Informal meetings on this project with colleagues have taken place online
Year(s) Of Engagement Activity 2019
 
Description British Society for Cardiovascular Research, Coronavirus and the cardiovascular system 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact BSCR reported there were 174 international attendees with a recording made available on the BSCR webpage together with a meeting report including the question and answer session. Positive feedback means BSCR will repeat the format next year.
Year(s) Of Engagement Activity 2020
URL https://bscr.org/event/bscr-autumn-2020-ol/
 
Description CLIRSPEC Summer School 2019 - Mid-infrared chemical and Biochemical sensors 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Undergraduate students
Results and Impact Farah Alimagham attended a Summer School on Clinical Spectroscopy - CLIRSPEC Summer School 2019 - approx. 50 attendees, international, 2th- 5th July 2019, Low Wood Bay, Windermere, UK - and gave a short (approx. 10 min) talk entitled "Mid-infrared chemical and Biochemical sensors", not directly mentioning our sensor due to IP issues (and the fact that at the time of the Summer School we were still filling for the patent), but she mentioned continuous monitoring using mid-IR and also her porous silicon on fibre-work which we had published.
Year(s) Of Engagement Activity 2019
 
Description CRUK Single Cell Workshop in Southampton 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Here we presented some preliminary results on using our protocol to explore ongoing chromosomal instability in ovarian cancer cell lines. The presentation was well received and provided validation of our approach for research use.
Year(s) Of Engagement Activity 2019
URL https://www.eventbrite.co.uk/e/single-cell-analysis-in-cancer-a-workshop-tickets-64716482742?utm_cam...
 
Description Centre33 quarterly staff meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Presentation of the project to a CPD session for Centre 33 practitioners. These engagement activities were integral to the development of the app but also for informing plans to for how it would successfully be applied within secondary schools for the next stage of the project
Year(s) Of Engagement Activity 2019
 
Description Clinical Neurosciences Away Day 2019, Wellcome Genome Campus Conference Centre 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Poster - internal departmental scientific conference. This MRC CiC project award ended on 30th April 2020. Conferences/meetings attended (at which we have presented our 31P MRS) before this date are listed above. No further conferences etc have been attended specifically on this 31P MRS project, due to Covid restrictions. Informal meetings on this project with colleagues have taken place online.
Year(s) Of Engagement Activity 2019
 
Description Clinical Validation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Catch -up school vision screening programme : 10,000 children have missed vision screening due to Covid in Cambridgeshire - collaboration between NWAFT, CUH and CCS Trusts will enable virtual vision screening to detect vision problems and avoid resultant visual impairment.

led to clinical use within CUH and Cambridgeshire Community Trust
Plans made for future related activity
Own/Colleagues reported change in views or opinions
Audience reported changes in views, opinions or behavious
Decisions made or influenced
Reduction in avoidable sight loss in children in Cambridgeshire
Year(s) Of Engagement Activity 2021
 
Description Coeliac UK online gala dinner 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Invited speaker at Coeliac UK online gala dinner, November 2020
Year(s) Of Engagement Activity 2020
 
Description Coeliac disease: can we diagnose it better? 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Representing advances in coeliac disease research in the UK at the 18th International Coeliac Disease Symposium, Paris, Sept 2019
Year(s) Of Engagement Activity 2008,2019
 
Description Focus group with GPs/clinicians 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Presentation and discussion around the technology and potential usability in the clinical setting
Year(s) Of Engagement Activity 2019
 
Description International Union of Basic and Clinical Pharmacology 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact IUPHAR reported nearly 100 international attendees with a meeting report available on the IUPHAR website.
Year(s) Of Engagement Activity 2020
 
Description Invited Speaker at MRC Centre for Regenerative Medicine, Edinburgh 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Requests for further information
Year(s) Of Engagement Activity 2020
 
Description Invited speaker at Columbia, Genetics and Development Seminar Series, New York 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited speaker at Columbia, Genetics and Development Seminar Series, New York, United States. (Virtual seminar) Requests for further information.
Year(s) Of Engagement Activity 2021
 
Description Invivoscribe's European dinner, European Haematology Association, Amsterdam 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact N/A
Year(s) Of Engagement Activity 2019
 
Description NIHR Child Health Technology 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Child Health Technology 2021 conference. The audience was a mix of clinicians, service users, engineers, NHS management, and other stakeholders.
Year(s) Of Engagement Activity 2021
URL https://cypmedtech.nihr.ac.uk/child-health-technology/
 
Description Pathological Society of Great Britain and Ireland 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact n/z
Year(s) Of Engagement Activity 2019
 
Description Pharmacology December 2020 BPS 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This is the flagship BPS meeting each year. Over 1100 people registered virtually including researchers of all career stages, clinicians, publishers and teachers. Focus was to disseminate information. Outcoems have been interactions with pharma and other researchers.
Year(s) Of Engagement Activity 2006,2020
 
Description Protein homeostasis in health and disease conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The work was presented at Protein homeostasis in health and disease conference, cold spring harbour, virtual conference, which was eventually held in November 2020. Virtual discussions were held, including new evidence from other groups about eIF2B that helped shape our experimental approaches.
Year(s) Of Engagement Activity 2021
 
Description Sensors Day 2018 "Design and Development of Mid-infrared Optical Sensors". 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Farah Alimagham also attended Sensors Day 2018, 10 October 2019, Fitzwilliam College, Cambridge (conference organised by the Sensor CDT), where she presented a poster entitled: "Design and Development of Mid-infrared Optical Sensors". It was very general and included continuous biofluid monitoring (as a general topic), bioreactor monitoring, and the use of meta materials for high-sensitivity chemical sensing.
Year(s) Of Engagement Activity 2018
 
Description Sensors in Medicine 2019, London 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact At Sensors in Medicine 2019 (see above), Farah Alimagham presented a poster featuring our sensor. The title was "Mid-IR Sensor Systems & Devices for Medical Diagnostics and Monitoring" and the authors were Farah Alimagham, Tanya Hutter, Keri Carpenter, Peter Hutchinson, and Stephen R Elliott. This won Best Poster prize.
Year(s) Of Engagement Activity 2019
 
Description The 60th ENC: Experimental Nuclear Magnetic Resonance Conference, Asilomar Conference Centre, California 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact presented our 31P MRS before this date are listed above. No further conferences etc have been attended specifically on this 31P MRS project, due to Covid restrictions. Informal meetings on this project with colleagues have taken place online.
Year(s) Of Engagement Activity 2019
 
Description The NIHR Applied Research Centre (ARC) East of England 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact These engagement activities are integral to the development of the app but also for informing plans to for how it would successfully be applied within secondary schools for the next stage of the project
Year(s) Of Engagement Activity 2021
 
Description University of Cambridge Primary School - "We are Scientists" 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact University of Cambridge Primary School: Our school outreach talk was part of an online event called "We are Scientists" at the University of Cambridge Primary School, which took place on 9th Nov 2020. Our talk was titled "We are Neuroscientists: studying the brain". It was a pre-recorded slide presentation with narration, followed by a live (via Microsoft Teams) Q&A session in which the audience of school-children asked us questions. The audience was local, approx. 60 staff and pupils. This talk is now on YouTube.
Year(s) Of Engagement Activity 2020
 
Description University of Cambridge Virtual Summer Festival of Learning "Neuroscience: unravelling the brain" 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact We achieved success with our pre-recorded talk, titled "Neuroscience: unravelling the brain" narrated by Prof Hutchinson, which was part of the University of Cambridge Virtual Summer Festival of Learning online programme (6th-24th July 2020), which was an international event. Ours was in the Free Open Talks section, free-to-access by members of the public - our talk had 190 views. This talk is now on YouTube.
Year(s) Of Engagement Activity 2020